Profile

Edward A. Levine, M.D.Wake Forest Baptist Health

Doctor Rating

4.6 out of 5

267 Ratings
30 Comments
 

Edward A. Levine, M.D.

Core Director,
Director-At-Large,
Chief,
Professor,


Clinical Interests

Breast Cancer, Esophageal Cancer, Esophageal Tumors, Gastrointestinal Tumors, Melanoma, Mesothelioma, Peritoneal Carcinomatosis, Sarcoma

Contact Information

New Patient Appointments: 336-716-WAKE
Returning Patient Appointments: 336-716-4276
Department: 336-716-0545

Email: elevine@wakehealth.edu

Insurance Accepted »

Media Medical Expert »

Education & Training

  • B.S., Northern Illinois University, 1981
  • M.D., Finch University of Health Sci/Chicago Med School, 1985
  • Residency, Surgery, Michael Reese Hosp/Med Ctr, 1990
  • Residency, Oncology, U Illinois Hospital, 1992

Memberships

  • Alpha Omega Alpha
  • Am Coll Of Surgeons
  • Am Hepato-Pancreato-Biliary
  • Assn Of Academic Surgery
  • Connective Tissue Oncology Soc
  • Nat'L Surgical Adjuvant For Br
  • North Carolina Medical Society
  • Soc Of Surg Of Alimentary Trac
  • Southern Assn For Oncology
  • Southern Medical Association
  • Southern Surgical Assn
  • Southern Surgical Congress
  • Winston-Salem Surgical Society

NPI Number

  • 1275518334
Edward A. Levine, M.D.

Doctor Rating

4.6 out of 5

267 Ratings
30 Comments
 

Edward A. Levine, M.D.

Core Director, Comprehensive Cancer Center
Director-At-Large, Comprehensive Cancer Center
Chief, Surgical Oncology
Professor, Surgical Oncology
Comprehensive Cancer Center
Office of Women in Medicine and Science

Research Interests

cancer/oncogenesis, genomics and proteomics, instrument development, physical/muscular function

Contact Information

Academic: 336-716-0545 | Department: 336-716-0545

Email: elevine@wakehealth.edu

Media Medical Expert »

Recent Publications

Schwarz L, Votanopoulos K, Morris D, Yonemura Y, Deraco M, Piso P, Moran B, Levine EA, Tuech JJ. Is the combination of distal pancreatectomy and cytoreductive surgery with HIPEC reasonable? Results of an International Multicenter study. Ann Surg. 2016;263(2):369-375.

Doud AN, Levine EA, Fino NF, Stewart JH, Shen P, Votanopoulos KI. Stoma creation and reversal after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2016;23(2):503-510.

Mogal HD, Levine EA, Russell G, Shen P, Stewart JH, Votanopoulos KI. Conditional survival after cytoreductive surgery with heated intraperitoneal chemotherapy for low- and high-grade appendiceal primaries. Ann Surg Oncol. 2016;23(2):534-538.

Blackham AU, Swords DS, Levine EA, Fino NF, Squires MH, Poultsides G, Fields RC, Bloomston M, Weber SM, Pawlik TM, Jin LX, Spolverato G, Schmidt C, Worhunsky D, Cho CS, Maithel SK, Votanopoulos KI. Is linitis plastica a contraindication for surgical resection: a multi-institution study of the U.S. Gastric Cancer Collaborative. Ann Surg Oncol. 2016;23(4):1203-1211.

Margonis GA, Amini N, Kim Y, Tran TB, Postlewait LM, Maithel SK, Wang TS, Evans DB, Hatzaras I, Shenoy R, Phay JE, Keplinger K, Fields RC, Moses LE, Weber SM, Salem A, Sicklick JK, Gad S, Yopp AC, Mansour JC, Duh QY, Seiser N, Solorzano CC,. Incidence of perioperative complications following resection of adrenocortical carcinoma and its association with long-term survival. World J Surg. 2016;40(3):706-714.

Margonis GA, Kim Y, Prescott JD, Tran TB, Postlewait LM, Maithel SK, Wang TS, Evans DB, Hatzaras I, Shenoy R, Phay JE, Keplinger K, Fields RC, Jin LX, Weber SM, Salem A, Sicklick JK, Gad S, Yopp AC, Mansour JC, Duh QY, Seiser N, Solorzano CC,. Adrenocortical carcinoma: impact of surgical margin status on long-term outcomes. Ann Surg Oncol. 2016;23(1):134-141.

Postlewait LM, Ethun CG, Tran TB, Prescott JD, Pawlik TM, Wang TS, Glenn J, Hatzaras I, Shenoy R, Phay JE, Keplinger K, Fields RC, Jin LX, Weber SM, Salem A, Sicklick JK, Gad S, Yopp AC, Mansour JC, Duh QY, Seiser N, Solorzano CC, Kiernan CM,. Outcomes of adjuvant mitotane after resection of adrenocortical carcinoma: a 13-institution study by the US Adrenocortical Carcinoma Group. J Am Coll Surg. 2016;222(4):480-490.

Amini N, Margonis GA, Kim Y, Tran TB, Postlewait LM, Maithel SK, Wang TS, Evans DB, Hatzaras I, Shenoy R, Phay JE, Keplinger K, Fields RC, Jin LX, Weber SM, Salem A, Sicklick JK, Gad S, Yopp AC, Mansour JC, Duh QY, Seiser N, Solorzano CC,. Curative resection of adrenocortical carcinoma: rates and patterns of postoperative recurrence. Ann Surg Oncol. 2016;23(1):126-133.

Ahmed S, Tran T, Levine EA, Weber S, Salem AI, Postlewait LM, Maithel SK, Wang T, Hatzaras I, Shenoy R, Phay J, Shirley L, Fields RC, Jin L, Pawlik TM, Prescott J, Sicklick J, Gad S, Yopp A, Mansour J, Duh Q, Seiser N, Solorzano CC, Kiernan CM,. Significance of intravenous thrombus in the management of adrenocortical carcinoma: prognosis and surgical implications [abstract]. Ann Surg Oncol. 2016;23(Suppl 1):S101.

Enomoto LM, Choudry MA, Pakrafter S, Magge D, Votanopoulos K, Levine EA, Turaga K, Pameijer C, Wong J. Multi-institution review of the role of cytoreductive surgery and heated intraperitoneal chemotherapy in metastatic gastric adenocarcinoma in the U.S. [abstract]. Ann Surg Oncol. 2016;23(Suppl 1):S22.

Gerry J, Postlewait LM, Maithel S, Prescott J, Wang T, Glenn JA, Phay J, Keplinger K, Fields RC, Jin L, Weber S, Salem AI, Sicklick J, Gad S, Yopp A, Mansour J, Duh Q, Seiser N, Solorzano CC, Kiernan CM, Votanopoulos K, Levine EA, Hatzaras I, Shenoy R. Lymphadenectomy for adrenocortical carcinoma: is there a therapeutic benefit? [abstract]. Ann Surg Oncol. 2016;23(Suppl 1):S100.

Hatzaras I, Rao R, Tran TB, Postlewait LM, Maithel SK, Prescott J, Pawlik TM, Wang T, Phay J, Fields RC, Jin L, Weber S, Salem AI, Sicklick J, Gad S, Yopp A, Mansour J, Duh Q, Seiser N, Solorzano CC, Kiernan CM, Votanopoulos K, Levine EA, Newman E,. Adjuvant radiation therapy in patients undergoing curative intent resection for adrenocortical carcinoma: a multi-institutional experience [abstract]. Ann Surg Oncol. 2016;23(Suppl 1):S99.

Wang A, Squires MH III, Melis M, Poultsides GA, Norton JA, Jin LX, Fields RC, Spolverato G, Pawlik TM, Votanopoulos KI, Levine EA, Schmidt C, Bloomston M, Cho CS, Weber S, Berman R, Pachter HL, Newman E, Staley CA, Maithel SK, Hatzaras I. Stage-specific prognostic effect of race in patients with resectable gastric adenocarcinoma: an 8-institution study of the US Gastric Cancer Collaborative. J Am Coll Surg. 2016;222(4):633-643.

Dodson RM, Mogal H, Russell G, Duckworth KE, Votanopoulos K, Shen P, Levine EA, McQuellon RP. Association of survival, postoperative morbidity and mortality following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy using quality of life assessments [abstract]. Ann Surg Oncol. 2016;23(Suppl 1):S35.

Levine EA, Votanopoulos KI, Qasem SA, Philip J, Cummins KA, Chou JW, Ruiz J, D'Agostino R, Shen P, Miller LD. Prognostic molecular subtypes of low-grade cancer of the appendix. J Am Coll Surg. 2016;222(4):493-503.

Mogal H, Chouliaras K, Levine EA, Shen P, Votanopoulos KI. Repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: review of indications and outcomes. J Gastrointest Oncol. 2016;7(1):129-142.

Randle RW, Swords DS, Levine EA, Fino NF, Squires MH, Poultsides G, Fields RC, Bloomston M, Weber SM, Pawlik TM, Jin LX, Spolverato G, Schmidt C, Worhunsky D, Cho CS, Maithel SK, Votanopoulos KI. Optimal extent of lymphadenectomy for gastric adenocarcinoma: A 7-institution study of the U.S. Gastric Cancer Collaborative. J Surg Oncol. 2016;():.

Cummins KA, Russell GB, Votanopoulos KI, Shen P, Stewart JH, Levine EA. Peritoneal dissemination from high-grade appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). J Gastrointest Oncol. 2016;7(1):3-9.

Jin LX, Sanford DE, Squires MH III, Moses LE, Yan Y, Poultsides GA, Votanopoulos KI, Weber SM, Bloomston M, Pawlik TM, Hawkins WG, Linehan DC, Schmidt C, Worhunsky DJ, Acher AW, Cardona K, Cho CS, Kooby DA, Levine EA, Winslow E, Saunders N,. Interaction of postoperative morbidity and receipt of adjuvant therapy on long-term survival after resection for gastric adenocarcinoma: results from the U.S. Gastric Cancer Collaborative. Ann Surg Oncol. 2016;():.

Doud AN, Randle RW, Clark CJ, Levine EA, Swett KR, Shen P, Stewart JH, Votanopoulos KI. Impact of distal pancreatectomy on outcomes of peritoneal surface disease treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2015;22(5):1645-1650.

Randle RW, Doud AN, Levine EA, Clark CJ, Swett KR, Shen P, Stewart JH, Votanopoulos KI. Peritoneal surface disease with synchronous hepatic involvement treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2015;22(5):1634-1638.

Votanopoulos KI, Russell G, Randle RW, Shen P, Stewart JH, Levine EA. Peritoneal surface disease (PSD) from appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): overview of 481 cases. Ann Surg Oncol. 2015;22(4):1274-1279.

Jin LX, Moses LE, Squires MH III, Poultsides GA, Votanopoulos K, Weber SM, Bloomston M, Pawlik TM, Hawkins WG, Linehan DC, Strasberg SM, Schmidt C, Worhunsky DJ, Acher AW, Cardona K, Cho CS, Kooby DA, Levine E, Winslow ER, Saunders ND,. Factors associated with recurrence and survival in lymph node-negative gastric adenocarcinoma: a 7-institution study of the US Gastric Cancer Collaborative. Ann Surg. 2015;262(6):999-1005.

Randle RW, Ahmed S, Levine EA, Fino NF, Swett KR, Stewart JH, Shen P, Votanopoulos KI. Significance of diabetes on morbidity and mortality following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. J Surg Oncol. 2015;111(6):740-745.

Spolverato G, Ejaz A, Kim Y, Squires MH, Poultsides G, Fields RC, Bloomston M, Weber SM, Votanopoulos K, Acher AW, Jin LX, Hawkins WG, Schmidt C, Kooby DA, Worhunsky D, Saunders N, Cho CS, Levine EA, Maithel SK, Pawlik TM. Prognostic performance of different lymph node staging systems after curative intent resection for gastric adenocarcinoma. Ann Surg. 2015;262(6):991-998.

Acher AW, Squires MH, Fields RC, Poultsides GA, Schmidt C, Votanopoulos KI, Pawlik TM, Jin LX, Ejaz A, Kooby DA, Bloomston M, Worhunsky D, Levine EA, Saunders N, Winslow E, Cho CS, Meredith K, Leverson G, Maithel SK, Weber SM. Can the risk of non-home discharge after resection of gastric adenocarcinoma be predicted: a seven-institution study of the US Gastric Cancer Collaborative. J Gastrointest Surg. 2015;19(2):207-216.

Kim Y, Ejaz A, Spolverato G, Squires MH, Poultsides G, Fields RC, Bloomston M, Weber SM, Votanopoulos K, Acher AW, Jin LX, Hawkins WG, Schmidt C, Kooby D, Worhunsky D, Saunders N, Cho CS, Levine EA, Maithel SK, Pawlik TM. Conditional survival after surgical resection of gastric cancer: a multi-institutional analysis of the US Gastric Cancer Collaborative. Ann Surg Oncol. 2015;22(2):557-564.

Faig J, Howard S, Levine EA, Casselman G, Hesdorffer M, Ohar JA. Changing pattern in malignant mesothelioma survival. Transl Oncol. 2015;8(1):35-39.

Randle RW, Griffith KF, Fino NF, Swett KR, Stewart JH IV, Shen P, Levine EA, Votanopoulos KI. Appendiceal goblet cell carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Surg Res. 2015;196(2):229-234.

Squires MH III, Kooby DA, Poultsides GA, Pawlik TM, Weber SM, Schmidt CR, Votanopoulos KI, Fields RC, Ejaz A, Acher AW, Worhunsky DJ, Saunders N, Levine EA, Jin LX, Cho CS, Bloomston M, Winslow ER, Russell MC, Cardona K, Staley CA, Maithel SK. Is it time to abandon the 5-cm margin rule during resection of distal gastric adenocarcinoma? A multi-institution study of the U.S. Gastric Cancer Collaborative. Ann Surg Oncol. 2015;22(4):1243-1251.

Kim Y, Spolverato G, Ejaz A, Squires MH, Poultsides G, Fields RC, Bloomston M, Weber SM, Votanopoulos K, Acher AW, Jin LX, Hawkins WG, Schmidt C, Kooby D, Worhunsky D, Saunders N, Levine EA, Cho CS, Maithel SK, Pawlik TM. A nomogram to predict overall survival and disease-free survival after curative resection of gastric adenocarcinoma. Ann Surg Oncol. 2015;22(6):1828-1835.

Bagante F, Tran TB, Postlewait LM, Maithel SK, Wang TS, Evans DB, Hatzaras I, Shenoy R, Phay JE, Keplinger K, Fields RC, Jin LX, Weber SM, Salem A, Sicklick JK, Gad S, Yopp AC, Mansour JC, Duh QY, Seiser N, Solorzano CC, Kiernan CM, Votanopoulos KI,. Neutrophil-lymphocyte and platelet-lymphocyte ratio as predictors of disease specific survival after resection of adrenocortical carcinoma. J Surg Oncol. 2015;112(2):164-172.

Blackham AU, Swords DS, Levine EA, Fitzgerald N, Squires MH, Poultsides GA, Fields RC, Bloomston M, Weber SM, Pawlik TM, Jin LDX, Spolverato G, Winslow E, Schmidt CR, Kooby DA, Worhunsky DJ, Saunders N, Cho CS, Maithel SK, Votanopoulos KI. Is linitis plastica a contraindication for surgical resection? A 7-institution study of the US Gastric Cancer Collaborative [abstract]. J Clin Oncol. 2015;33(3 Suppl):118.

Dann GC, Squires MH III, Postlewait LM, Kooby DA, Poultsides GA, Weber SM, Bloomston M, Fields RC, Pawlik TM, Votanopoulos KI, Schmidt CR, Ejaz A, Acher AW, Worhunsky DJ, Saunders N, Levine EA, Jin LX, Cho CS, Winslow ER, Russell MC,. An assessment of feeding jejunostomy tube placement at the time of resection for gastric adenocarcinoma: a seven-institution analysis of 837 patients from the U.S. Gastric Cancer Collaborative. J Surg Oncol. 2015;112(2):195-202.

Gholami S, Janson L, Worhunsky DJ, Tran TB, Squires MH III, Jin LX, Spolverato G, Votanopoulos KI, Schmidt C, Weber SM, Bloomston M, Cho CS, Levine EA, Fields RC, Pawlik TM, Maithel SK, Efron B, Norton JA, Poultsides GA. Number of lymph nodes removed and survival after gastric cancer resection: an analysis from the US Gastric Cancer Collaborative. J Am Coll Surg. 2015;221(2):291-299.

Squires MH III, Kooby DA, Poultsides GA, Weber SM, Bloomston M, Fields RC, Pawlik TM, Votanopoulos KI, Schmidt CR, Ejaz A, Acher AW, Worhunsky DJ, Saunders N, Levine EA, Jin LX, Cho CS, Winslow ER, Russell MC, Staley CA, Maithel SK. Effect of perioperative transfusion on recurrence and survival after gastric cancer resection: a 7-institution analysis of 765 patients from the US Gastric Cancer Collaborative. J Am Coll Surg. 2015;221(3):767-777.

Randle RW, Swords DS, Levine EA, Fitzgerald N, Squires MH, Poultsides GA, Fields RC, Bloomston M, Weber SM, Pawlik TM, Jin LX, Spolverato G, Winslow E, Schmidt CR, Dooby DA, Worhunsky DJ, Saunders N, Cho CS, Maithel SK, Votanopoulos KI. Optimal extent of lymphadenectomy in gastric adenocarcinoma: a seven-institution study of the US Gastric Cancer Collaborative [abstract]. J Clin Oncol. 2015;33(3 Suppl):115.

Allen S, Levine EA, Lesko N, Howard-Mcnatt M. Is excisional biopsy and chemoprevention warranted in patients with atypical lobular hyperplasia on core biopsy?. Am Surg. 2015;81(9):876-878.

Howard-McNatt M, Isom S, Hurt G, Votanopoulos KI, Levine EA. A prospective study of preoperative BRCA status determination and surgical choice [abstract]. Ann Surg Oncol. 2015;22(Suppl 1):S56.

Randle RW, Swords D, Levine EA, Fino NF, Squires MH, Poultsides GA, Fields RC, Bloomston M, Weber SM, Pawlik TM, Jin LX, Spolverato G, Winslow ER, Schmidt CR, Kooby DA, Worhunsky DJ, Saunders ND, Cho CS, Maithel SK, Votanopoulos KI. Optimal extent of lymphadenectomy in gastric adenocarcinoma: a 7-institution study of the US Gastric Cancer Collaborative [abstract]. Ann Surg Oncol. 2015;22(Suppl 1):S164-S165.

Shen P, Fino N, Levine EA, Eversole P, Clark C. Bile duct surgery in the treatment of hepatobiliary and gallbladder malignancies: effects of hepatic and vascular resection on outcomes. HPB (Oxford). 2015;17(12):1066-1073.

Saunders ND, Kearney JF, Lyon EH, Bloomston M, Squires MH, Kooby DA, Pawlik TM, Weber SM, Poultsides GA, Votanopoulos KI, Fields RC, Ejaz A, Acher AW, Worhunsky DJ, Jin LX, Levine EA, Cho CS, Winslow ER, Cardona K, Staley CA, Maithel SK, Schmidt CR. The ACS-NSQIP surgical risk calculator lacks enough sensitivity to risk stratify patients with gastric cancer at academic medical centers [abstract]. Ann Surg Oncol. 2015;22(Suppl 1):S136.

Tran TB, Worhunsky DJ, Squires MH, Jin LX, Spolverato G, Votanopoulos KI, Cho CS, Weber SM, Schmidt C, Levine EA, Bloomston M, Fields RC, Pawlik TM, Maithel SK, Norton JA, Poultsides GA. To Roux or not to Roux: a comparison between Roux-en-Y and Billroth II reconstruction following partial gastrectomy for gastric cancer. Gastric Cancer. 2015;():.

Tran TB, Hatzaras I, Worhunsky DJ, Vitiello GA, Squires MH III, Jin LX, Spolverato G, Votanopoulos KI, Schmidt C, Weber S, Bloomston M, Cho CS, Levine EA, Fields RC, Pawlik TM, Maithel SK, Norton JA, Poultsides GA. Gastric remnant cancer: a distinct entity or simply another proximal gastric cancer?. J Surg Oncol. 2015;112(8):877-882.

Kim Y, Margonis GA, Prescott JD, Tran TB, Postlewait LM, Maithel SK, Wang TS, Evans DB, Hatzaras I, Shenoy R, Phay JE, Keplinger K, Fields RC, Jin LX, Weber SM, Salem AI, Sicklick JK, Gad S, Yopp AC, Mansour JC, Duh QY, Seiser N,. Nomograms to predict recurrence-free and overall survival after curative resection of adrenocortical carcinoma. JAMA Surg. 2015;():.

Kim Y, Margonis GA, Prescott JD, Tran TB, Postlewait LM, Maithel SK, Wang TS, Glenn JA, Hatzaras I, Shenoy R, Phay JE, Keplinger K, Fields RC, Jin LX, Weber SM, Salem A, Sicklick JK, Gad S, Yopp AC, Mansour JC, Duh QY, Seiser N,. Curative surgical resection of adrenocortical carcinoma: determining long-term outcome based on conditional disease-free probability. Ann Surg. 2015;():.

Tran TB, Worhunsky DJ, Squires MH III, Jin LX, Spolverato G, Votanopoulos KI, Schmidt C, Weber S, Bloomston M, Cho CS, Levine EA, Fields RC, Pawlik TM, Maithel SK, Norton JA, Poultsides GA. Outcomes of gastric cancer resection in octogenarians: a multi-institutional study of the U.S. Gastric Cancer Collaborative. Ann Surg Oncol. 2015;22(13):4371-4379.

Valero-Elizondo J, Kim Y, Prescott JD, Margonis GA, Tran TB, Postlewait LM, Maithel SK, Wang TS, Glenn JA, Hatzaras I, Shenoy R, Phay JE, Keplinger K, Fields RC, Jin LX, Weber SM, Salem A, Sicklick JK, Gad S, Yopp AC, Mansour JC, Duh QY,. Incidence and risk factors associated with readmission after surgical treatment for adrenocortical carcinoma. J Gastrointest Surg. 2015;19(12):2154-2161.

Mogal HD, Levine EA, Fino NF, Obiora C, Shen P, Stewart JH, Votanopoulos KI. Routine admission to intensive care unit after cytoreductive surgery and heated intraperitoneal chemotherapy: not always a requirement. Ann Surg Oncol. 2015;():.

Margonis GA, Kim Y, Tran TB, Postlewait LM, Maithel SK, Wang TS, Glenn JA, Hatzaras I, Shenoy R, Phay JE, Keplinger K, Fields RC, Jin LX, Weber SM, Salem A, Sicklick JK, Gad S, Yopp AC, Mansour JC, Duh QY, Seiser N, Solorzano CC, Kiernan CM,. Outcomes after resection of cortisol-secreting adrenocortical carcinoma. Am J Surg. 2015;():.

All Publications

For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.

For a list of earlier publications, visit the Carpenter Library Publication Search.

Professor, Surgical Oncology

Clinical Interests

Breast Cancer, Esophageal Cancer, Esophageal Tumors, Gastrointestinal Tumors, Melanoma, Mesothelioma, Peritoneal Carcinomatosis, Sarcoma
Edward A. Levine, M.D.

Edward A. Levine, M.D.

Core Director, Comprehensive Cancer Center
Director-At-Large, Comprehensive Cancer Center
Chief, Surgical Oncology
Professor, Surgical Oncology
Comprehensive Cancer Center
Office of Women in Medicine and Science

Doctor Rating

4.6 out of 5

Edward A. Levine, M.D.267 Ratings
30 Comments


 

Doctor Ratings

The overall Patient Rating score is the average of responses to the nine questions listed below. The questions are from the Press Ganey Patient Satisfaction Survey. Responses are measured on a 1 to 5 scale, where 1 represents "very poor" and 5 represents "very good."
Press Ganey Patient Satisfaction Survey

CP concern for questions/worries
4.7
CP efforts to include in decisions
4.7
CP explanations of prob/condition
4.8
CP spoke using clear language
4.8
Friendliness/courtesy of CP
4.8
Likelihood of recommending CP
4.8
Patients' confidence in CP
4.9
Time CP spent with patient
4.6
Wait time at clinic
3.6



Patient Comments

Comments are taken from the Care Provider section of the Press Ganey Patient Satisfaction Survey. Comments are posted exactly as they are written. Comments are added weekly. To protect patient privacy and confidentiality, patient names are not included.

2/18/2016

He is the best, I would and do recommend him to everyone who is going through what I went through he is God sent and a blessing to everyone he touch.

2/12/2016

Very likely.

2/8/2016

so satisfied

1/27/2016

After 5 years *Dr. Levine pronounced me CANCER FREE.

1/25/2016

Once the doctor came it, I was very please with their care.

1/12/2016

Everyone was very informative, explaining everything I was concerned about. Excellent care and I will recommend them to everyone.

1/7/2016

I would and have already recommend to family & friends that has needs in this area.

12/16/2015

I think Dr. Levine's experience and knowledge of cancer is excellent. It would be a better experience if the clinic could be run more efficient respecting the patients it serves.

12/16/2015

Dr. Levine is an excellent doctor. After two surgeries with him, I'd HIGHLY recommend him. Dr. Levine is definitely my surgeon of choice! A+++++

12/15/2015

Dr. Levine is an exceptional physician.

11/30/2015

*Dr. Levine is my 'go to' guy. He gave me back my life!

11/24/2015

This was my first visit to see *Dr. LeVine. He was wonderful. Very friendly, knowledgeable & compassionate.

11/24/2015

Experience with *Dr. Levine could not be better.

11/18/2015

*Dr.Levine is FABULOUS!

11/10/2015

Would definitely recommend this Dr to anyone. My mother has had a history with him and he has always been professional in his dealings with her. Explains information so that she can understand. She has dementia, and he explains information well.

10/26/2015

Good

10/26/2015

I am totally comfortable with Dr Levine and his staff. I've never felt a connect like the way I felt with them. I feel they truly, deeply care for their patients. I was totally comfortable with Dr Levine the very first time I met him. I knew and felt he knew exactly what he was doing. I feel he is the best at what he does. I firmly believe that.

10/7/2015

Everyone showed excellent skills, care and support for and to me.

8/6/2015

I have had breast cancer 3 times since 2001, Dr. Levine was my surgeon of choice each time. There is no better Surgeon or care anywhere.

7/31/2015

*Dr. Levine has my utmost respect.

7/29/2015

I felt *Dr. Levine was reading my mind, answering my questions before I asked & doing so honestly. I was scared & apprehensive & he made me feel at ease.

7/27/2015

Dr. Levine was excellent. The Resident was kind and fairly knowledgeable. The NP was tremendous!

7/19/2015

Have recommended him many times to others.

6/30/2015

Dr. Levine was respectful, considerate of my family member, and fully aware of my health history. He has always treated me as a person, not a medical chart. On this visit in particular, he spent a great deal of time with me and made sure to answer all of my questions. Dr. Levine is the reason I have returned to this cancer center for additional treatment rather than going to a community cancer center closer to home.

6/24/2015

dr Levine is a very caring person. the hospital is very fortunate to have him

6/12/2015

I would recommend this care provider for any surgical oncology

6/8/2015

Great Dr. just follow-up too long in room!

6/3/2015

Dr. Levine is the backbone that supports the principles of a research and teaching hospital.

5/18/2015

Dr. Levine is a true professional.

5/11/2015

*Dr. Levine & his staff are extra good!!

Quick Reference

Request an Appointment
New Patients

336-716-WAKE
888-716-WAKE

Existing patients may contact the clinic directly.
Find a Doctor Ways to Give
USNWR 2015-2016Magnet Hospital RecognitionConsumer Choice2015 Best DoctorsJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.